IL125711A0 - Human metabotropic glutamate receptor - Google Patents

Human metabotropic glutamate receptor

Info

Publication number
IL125711A0
IL125711A0 IL12571197A IL12571197A IL125711A0 IL 125711 A0 IL125711 A0 IL 125711A0 IL 12571197 A IL12571197 A IL 12571197A IL 12571197 A IL12571197 A IL 12571197A IL 125711 A0 IL125711 A0 IL 125711A0
Authority
IL
Israel
Prior art keywords
mglur
metabotropic glutamate
glutamate receptor
human metabotropic
modulate
Prior art date
Application number
IL12571197A
Other languages
English (en)
Original Assignee
Nps Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nps Pharma Inc filed Critical Nps Pharma Inc
Publication of IL125711A0 publication Critical patent/IL125711A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Polyamides (AREA)
IL12571197A 1996-02-21 1997-02-20 Human metabotropic glutamate receptor IL125711A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/604,298 US6084084A (en) 1996-02-21 1996-02-21 Human metabotropic glutamate receptor
PCT/US1997/009025 WO1997048724A2 (en) 1996-02-21 1997-02-20 Human metabotropic glutamate receptor

Publications (1)

Publication Number Publication Date
IL125711A0 true IL125711A0 (en) 1999-04-11

Family

ID=24419059

Family Applications (2)

Application Number Title Priority Date Filing Date
IL12571197A IL125711A0 (en) 1996-02-21 1997-02-20 Human metabotropic glutamate receptor
IL125711A IL125711A (en) 1996-02-21 1998-08-09 Human metabotropic glutamate receptor

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL125711A IL125711A (en) 1996-02-21 1998-08-09 Human metabotropic glutamate receptor

Country Status (10)

Country Link
US (3) US6084084A (enExample)
EP (1) EP0882065B1 (enExample)
JP (1) JP2000506392A (enExample)
AT (1) ATE369385T1 (enExample)
AU (1) AU719841B2 (enExample)
CA (1) CA2246751A1 (enExample)
DE (1) DE69737990T2 (enExample)
ES (1) ES2292193T3 (enExample)
IL (2) IL125711A0 (enExample)
WO (1) WO1997048724A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521297A (en) * 1993-06-04 1996-05-28 Salk Institute Biotechnology/Industrial Associates Nucleic acids encoding human metabotropic glutamate receptors
ES2308779T3 (es) * 1995-07-26 2008-12-01 Astrazeneca Ab Receptores quimericos y metodos para identificar compuestos activos en los receptores de glutamato metabotropico y el uso de tales compuestos en el tratamiento de trastornos y enfermedades neurologicas.
US6221609B1 (en) 1996-07-03 2001-04-24 Eli Lilly And Company Isolate nucleic acid encoding human MGLUR8
JP2002510480A (ja) * 1998-04-03 2002-04-09 エヌピーエス ファーマシューティカルズ インコーポレーテッド Ｇ−蛋白融合受容体およびキメラｇａｂａｂ受容体
US7262280B1 (en) 1998-04-03 2007-08-28 Nps Pharmaceuticals, Inc. G-protein fusion receptors and constructs encoding same
EP1662255A3 (en) * 1998-08-18 2006-09-13 The Johns Hopkins University School Of Medicine Homer interacting proteins
JP2002523056A (ja) * 1998-08-18 2002-07-30 ザ ジョンズ ホプキンス ユニバーシティー スクール オブ メディシン Ｈｏｍｅｒ相互作用タンパク質
JP4714342B2 (ja) * 1998-08-31 2011-06-29 ザ プラヴアスト フエロウス アンド スカラース オブ ザ カレツヂ オブ ザ ハリー アンド アンデイヴアイデツド トリニテイ オブ クイーン エリザベス ニヤー ダブリン コアグラーゼ陰性スタフィロコカス菌に由来のポリペプチド及びポリヌクレオチド
US20030166554A1 (en) * 2001-01-16 2003-09-04 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
US20030185754A1 (en) * 2001-01-16 2003-10-02 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
US6620850B2 (en) * 2001-09-19 2003-09-16 University Of Florida Materials and methods for treatment of neurological disorders involving overactivation of glutamatergic ionotropic receptors
EP1456418A4 (en) * 2001-12-20 2006-07-26 Merck & Co Inc IDENTIFICATION OF NEW POLYMORPHIC LOCATIONS IN THE HUMAN MGLUR8 GEN AND USES THEREOF
EP1531855A4 (en) * 2002-01-10 2009-07-22 Osteotrophin Llc TREATMENT OF BONE DISEASES WITH SKELETTAL ANABOLIKA
AU2003298014A1 (en) * 2002-12-04 2004-06-23 Diadexus, Inc. Compositions, splice variants and methods relating to colon specific genes and proteins
US20050186658A1 (en) * 2003-10-17 2005-08-25 Nps Pharmaceuticals, Inc. Chimeric metabotropic glutamate receptors and uses thereof
WO2005073730A1 (en) * 2004-01-31 2005-08-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human metabotropic glutamate receptor 8 (mglur8)
ATE540048T1 (de) * 2004-10-14 2012-01-15 Carnegie Inst Of Washington Neurotransmittersensoren und verfahren zu ihrer verwendung
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
US8889950B2 (en) * 2006-07-28 2014-11-18 The George Washington University Repression of AtGLR3.2 increases plant biomass
US7424876B2 (en) * 2006-10-06 2008-09-16 Ford Global Technologies, Llc Pushrod engine with multiple independent lash adjusters for each pushrod
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
SI2203439T1 (sl) 2007-09-14 2011-05-31 Ortho Mcneil Janssen Pharm 1',3'-disubstituirani 4-fenil-3,4,5,6-tetrahidro-2H-1'H-(1,4')bipiridinil-2'-oni
US9217024B2 (en) 2007-12-18 2015-12-22 Acumen Pharmaceuticals, Inc. ADDL receptor polypeptides, polynucleotides and host cells for recombinant production
WO2010011404A2 (en) * 2008-05-20 2010-01-28 Eos Neuroscience, Inc. Vectors for delivery of light-sensitive proteins and methods of use
EP2344470B1 (en) 2008-09-02 2013-11-06 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
JP5690277B2 (ja) 2008-11-28 2015-03-25 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
CN102439008B (zh) 2009-05-12 2015-04-29 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
BRPI1010831A2 (pt) 2009-05-12 2016-04-05 Addex Pharmaceuticals Sa derivados de 1,2,4-triazolo[4,3-a]piridina e seu como moduladores alostéricos positivos de receptores de mglur2
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
AU2011328203B2 (en) 2010-11-08 2015-03-19 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
MX386697B (es) 2014-01-21 2025-03-19 Janssen Pharmaceutica Nv Combinaciones que comprenden agonistas ortostericos o moduladores alostericos positivos del receptor glutamatergico metabotropico de subtipo 2 y su uso
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
US11254744B2 (en) 2015-08-07 2022-02-22 Imaginab, Inc. Antigen binding constructs to target molecules
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
EP3612210A4 (en) 2017-04-19 2021-01-27 Board Of Regents, The University Of Texas System MANIPULATED ANTIGEN RECEPTORS EXPRESSING IMMUNE CELLS
US12473336B2 (en) 2018-02-21 2025-11-18 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3829583A (en) * 1971-02-20 1974-08-13 Hayashibara Ken Mixture of maltobionic acid and monosodium glutamate as a food seasoning
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5177011A (en) * 1988-08-18 1993-01-05 Calgene, Inc. Plant elongation factor promoters, coding sequences and uses
JP2944721B2 (ja) * 1990-08-22 1999-09-06 生化学工業株式会社 エンドトキシンの測定剤
NZ240921A (en) * 1990-12-12 1994-06-27 Zymogenetics Inc G protein coupled glutamate receptor (neurotransmitters), recombinant production
ATE313321T1 (de) * 1991-08-23 2006-01-15 Nps Pharma Inc Kalzium-rezeptor aktive verbindungen
CN1192011C (zh) * 1991-08-23 2005-03-09 Nps药物有限公司 对钙受体具活性的芳烷基胺化合物
IL105587A0 (en) * 1992-05-08 1993-09-22 Lilly Co Eli Human metabotropic glutamate receptor and related dna compounds
EP0642589A4 (en) * 1992-05-11 1997-05-21 Ribozyme Pharm Inc METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION.
AU695641B2 (en) * 1993-09-20 1998-08-20 Novartis Ag Human metabotropic glutamate receptor subtypes (HMR4, HMR6, HMR7) and related DNA compounds
US6274330B1 (en) * 1993-12-30 2001-08-14 Zymogenetics, Inc. L-AP4 sensitive glutamate receptors
WO1995031539A1 (en) * 1994-05-16 1995-11-23 Human Genome Sciences, Inc. Neurotransmitter transporter
ES2308779T3 (es) * 1995-07-26 2008-12-01 Astrazeneca Ab Receptores quimericos y metodos para identificar compuestos activos en los receptores de glutamato metabotropico y el uso de tales compuestos en el tratamiento de trastornos y enfermedades neurologicas.

Also Published As

Publication number Publication date
AU719841B2 (en) 2000-05-18
EP0882065A2 (en) 1998-12-09
ATE369385T1 (de) 2007-08-15
IL125711A (en) 2006-09-05
EP0882065B1 (en) 2007-08-08
US6077675A (en) 2000-06-20
DE69737990D1 (de) 2007-09-20
US6084084A (en) 2000-07-04
AU3715697A (en) 1998-01-07
JP2000506392A (ja) 2000-05-30
WO1997048724A2 (en) 1997-12-24
ES2292193T3 (es) 2008-03-01
CA2246751A1 (en) 1997-12-24
WO1997048724A3 (en) 1998-03-26
US6051688A (en) 2000-04-18
DE69737990T2 (de) 2008-09-11

Similar Documents

Publication Publication Date Title
IL125711A0 (en) Human metabotropic glutamate receptor
UA42747C2 (uk) Похідні пептиду,фармацевтична композиція та спосіб стимулювання секреції гормону росту
NO985975L (no) Blandinger og fremgangsmÕter for frembringelse av farmakologisk aktive preparater og anvendelser derav
PL314300A1 (en) Peptide-type compounds and their therapeutic application as inhibitors of metalloproteinases
AU6602296A (en) Chimeric receptors and methods for identifying compounds active at metabotropic glutamate receptors and the use of such compounds in the treatment of neurological disorders and diseases
AU1373499A (en) Use of 9-deoxy-2', 9-alpha-methano-3- oxa-4,5,6- trinor-3, 7-(1',3'-interphenylene) -13,14-dihydro- prostaglandin f1 to treat peripheral vascular disease
DE69839815D1 (de) Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten
WO2003103575A3 (en) Compounds, compositions, and methods
DE60042137D1 (de) Rekombinante alpha-l-iduronidase und behandlung von durch diese hervorgerufene mangelerkrankungen
CA2165824A1 (fr) Utilisation du modafinil pour la fabrication d'un medicament ayant un effet sur les apnees du sommeil et les troubles ventilatoires d'origine centrale
NZ314839A (en) 1,25-Dihydroxy-16,23Z-diene-20-epi-16-ene-cholecalciferol (Vitamin D3) analogues
ATE403672T1 (de) Oral aktive fraktion der momordica charantia, ihre aktiven peptide und ihre verwendung bei der behandlung des diabetes
AU3376297A (en) Human thyrotropin receptor compositions and use thereof
AU3414295A (en) Methods and compounds active at metabotropic glutamate receptors useful for treatment of neurological disorders and diseases
MX9604023A (es) Compuestos heterociclicos, su preparacion y su uso.
ZA200107283B (en) Vascular adhesion molecules and modulation of their function.
EP0322226A3 (en) Site-directed mutagenesis modified glycoprotein hormones and methods of use
GR3006815T3 (enExample)
AU691336B2 (en) Use of 2,4-diamino pyrimidine 3-oxide or a salt thereof for treating collagen maturation and structuring disorders
EP1199361A3 (en) Glycoprotein hormone receptor molecules. Their uses
EP0196921A3 (en) Recombinant human renin
AP2000002004A0 (en) Method of treatment for dermatological disorders and compositions therefor.
NZ328915A (en) use of sulbutiamine to treat psychomotor and psychointellectual disorders
IL124729A (en) Use of bismuth for the manufacture of compositions for the treatment and prevention of gastrointestinal disorders
ES8500055A1 (es) Procedimiento para la obtencion de un medicamento a base de un derivado de pirazolinona.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed